Hypertension is prevalent in 49% of renal transplant recipients. Chronic rejection and impaired renal function may account for mild to moderate hypertension in most patients. The development of severe hypertension following renal transplantation, however, suggests TRAS, which is amenable to surgical correction with a high probability of success. Post-transplant hypertension did not correlate with renal diagnoses, sex, donor source and/or prednisone dose.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Open-label randomised clinical trial investigating whether robot-assisted kidney transplantation can reduce surgical complications compared to open kidney transplantation (ORAKTx): study protocol for a randomised clinical trial.
Trials
January 2025
Urological Research Unit, Department of Urology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background: Kidney transplantation is the ultimate treatment for end-stage kidney disease. Function of the kidney graft is not only dependent on medical factors but also on a complication-free surgical procedure. In the event of major surgical complications, the kidney graft is potentially lost and the patient will return to the waiting list which may be long.
View Article and Find Full Text PDFTrained immunity: from kidney failure to organ transplantation.
Nat Rev Nephrol
January 2025
Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.
'BJUI Clinical Dilemma': the incidental small renal mass in a solitary kidney.
BJU Int
January 2025
Department of Urology, University of California, Irvine, Orange, CA, USA.
Second Time Around: Increased Rate of Living Donation From Repeat Organ Donors.
Clin Transplant
January 2025
Department of Surgery, NYU Langone, New York, New York, USA.
Introduction: Some living organ donors will decide to donate again at a later date. Evidence has indicated that this practice may have increased in recent years. We evaluated the incidence and outcomes of this practice to inform counseling of potential repeat donors.
View Article and Find Full Text PDFSerum amyloid P (PTX2) attenuates hepatic fibrosis in mice by inhibiting the activation of fibrocytes and HSCs.
Hepatol Commun
November 2024
Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Background: Liver fibrosis is caused by chronic toxic or cholestatic liver injury. Fibrosis results from the recruitment of myeloid cells into the injured liver, the release of inflammatory and fibrogenic cytokines, and the activation of myofibroblasts, which secrete extracellular matrix, mostly collagen type I. Hepatic myofibroblasts originate from liver-resident mesenchymal cells, including HSCs and bone marrow-derived CD45+ collagen type I+ expressing fibrocytes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!